We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Arvinas

News List

Arvinas and Pfizer enter up to $2.4bn deal to develop breast cancer drug pharmaceutical-technology
July 26, 2021
Arvinas and Pfizer have entered an international partnership to jointly develop and market the former’s investigational therapy, ARV-471, for breast cancer.
Pfizer makes $830m drug discovery pact with Arvinas pharmafile
January 05, 2018
Arvinas has managed to secure another big pharma collaboration, after it announced that Pfizer had signed a research and licensing agreement.
Genentech Dumps Another $650M in New Haven Biotech Arvinas biospace
November 16, 2017
New Haven, Conn.-based Arvinas expanded an ongoing licensing deal with Genentech. The agreement is to develop new drugs using Arvinas’ PROTAC technology. The original deal was inked in October 2015.
Arvinas Appoints President of Research and Development and Chief Scientific Officer americanpharmaceuticalreview
January 06, 2017
Arvinas, a private biotechnology company creating a new class of drugs based on protein degradation, has appointed Dr. John Houston as President of Research and Development and Chief Scientific Officer to lead discovery research, translational research an